Efficacy and Safety of Resveratrol and Lipoic Acid Transdermal Patch for Lipolysis in Overweight Volunteers

Lipolysis Clinical Trial

Official title:

Efficacy and Safety of Resveratrol and Lipoic Acid Transdermal Patch for Lipolysis in Overweight Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03062163
• Other study ID #: nanolab817
• Status: Completed
• Phase: N/A
• First received: February 13, 2017
• Last updated: February 20, 2017
• Start date: January 23, 2017
• Est. completion date: February 6, 2017

Study information

• Verified date: February 2017
• Source: Chulalongkorn University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the lipolysis effect of resveratrol and lipoic acid transdermal patch in overweight volunteers

Description:

66 participants with overweight received a resveratrol and lipoic acid transdermal patch treatment. The treatment areas have been treated including left and right arms. Subjects were evaluated using standardized measurements of body weight and circumference of arms at baseline and 2 weeks follow-up visits. Evaluation of physician were also measured.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: February 6, 2017
• Est. primary completion date: February 6, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• healthy volunteers with BMI > 23

Exclusion Criteria:

• resveratrol or lipoic acid allergies

Related Conditions & MeSH terms

• Lipolysis
• Overweight

Intervention

Other:
• Resveratrol lipoic Acid
Transdermal patch loaded with resveratrol and lipoic acid
• Placebo
Transdermal patch loaded with normal saline

Locations

Country	Name	City	State
Thailand	Faculty of Medicine, Chulalongkorn University	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	fat thickness measured	fat thickness measurement by ultrasound	2 weeks